Investor Ideas #Potcasts 541, #Cannabis News and #Stocks on the Move; (TSXV: $KHRN.V) (TSX: $VIVO.TO) (TSX: $VLNS.TO) (OTCQX: $VLNCF) (TSXV: $PCLO.V)
Delta, Kelowna, BC, March 12, 2021 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2021/031221-StocksToWatch.mp3
Read this in full
at https://www.investorideas.com/news/2021/cannabis-potcasts/03121KHRN-VIVO-VLNS-PCLO.asp
Hear the investor ideas potcast on Spotify
Hear Investor ideas cannabis potcast on iTunes
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
In
today’s podcast we look at a few public and private company announcements.
Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF), a vertically integrated
cannabis leader with core operations in Latin America and Europe, announced that the Company has successfully
exported its registered Colombian cannabis strains, in the form of live clones,
to Europe. This significant milestone represents the first shipment of medical
cannabis live plant material to Europe from Colombia and is expected to
accelerate access to European markets as the Company executes on its asset
light growth strategy in the United Kingdom and Germany.
Through
its EU-GMP certified supply chain partners in Europe, Khiron plans to introduce
branded, cannabis-based medicinal products based on those already distributed
by the Company in Colombia and Peru. Over the last year, more than 13,000
written prescriptions for extracts, formulated with Khiron´s registered
cannabis strains, have been issued to patients in Latin America. As clinical
evidence mounts, safety and efficacy data arising from Khiron's wholly-owned
clinics in Latin America is expected to serve as a cornerstone of the Company's
European medical education program.
Tejinder
Virk, President of Khiron Europe, commented: "Our experience in Colombia
and Europe tells us that doctors require solid clinical evidence to feel
confident that medical cannabis is the right treatment for their patients. By
exporting our Colombian cannabis strains, we will be able to bring our Latin
American extracts to European patients, resulting in wider choices for doctors,
and safer, more efficacious patient outcomes. Additionally, this import
provides an opportunity to accelerate speed to market, optimize our global
diversified supply chain and maximize economics."
Khiron's
vertically integrated seed-to-patient business model is currently experiencing
tremendous growth in Colombia. To date, Khiron medical cannabis products have
shown strong evidence as alternative treatments for ailments such as chronic
pain, anxiety, insomnia, depression, epilepsy, migraines, and Parkinson's
Disease. With the proof of concept now validated in Colombia, the Company plans
to build upon its success in new markets.
VIVO
Cannabis Inc. (TSX: VIVO) (OTCQX: VVCIF) announced that its Vanluven facility in
Napanee Ontario has received EU-GMP (European Union Good Manufacturing
Practices) certification from Germany's Brandenburg health authority, the
Landesamt für Arbeitsschutz, Verbraucherschutz und Gesundheit
("LAVG"). The certification
takes effect immediately and enables VIVO, through its ABcann Medicinals
subsidiary, to export product for sale into European and other markets
requiring products to be manufactured under the rigorous GMP standards.
At the same time VIVO's German
subsidiary Beacon Medical Germany GmbH received an import licence from the
authority to import medical cannabis flowers from Napanee to Germany and the
EU.
VIVO's President of European
Operations, Andreas Sander said, "We are very excited about VIVO's receipt
of GMP certification from the German health authority of the state of
Brandenburg. This is a major step forward in VIVO's commitment to expand our
medical cannabis business. It will allow
us to start to provide patients, physicians and pharmacists with high quality
medical cannabis flowers in Germany, the rest of Europe and beyond. It is a
significant achievement that will help differentiate VIVO from many of its
peers."
VIVO wants to thank the dedication
of its GMP team for bringing this multi-year project to this successful
milestone. GMP certification requires
significant resources to achieve and to maintain. EU-GMP certification will likely provide VIVO
the opportunity to pursue distribution opportunities not only in Germany but
across the EU and in other global markets in which EU-GMP certification is
required for market access. The Company is now working to achieve the first
European sales of its Beacon Medical™ products, expected by Q3.
The
Valens Company Inc. (TSX: VLNS) (OTCQX: VLNCF), a leading manufacturer of cannabis products, announced that it has entered into a custom
manufacturing agreement with Experion
Biotechnologies Inc. (TSX-V: EXP) (OTCQB: EXPFF), a partner of the Company's
recently acquired LYF Food Technologies Inc. Experion is a licensed cultivator,
processor and brand builder with a portfolio of premium products.
Under the agreement, Valens will
provide end-to-end pre-roll manufacturing and product distribution services to
Experion – the Company's first custom manufacturing agreement of this nature
following the receipt of its Health Canada licence amendment to sell dried
cannabis products. In partnership, Valens and Experion will expand the pre-roll
offering for Experion's popular Citizen Stash brand, which is focused on
providing consumers the highest quality handcrafted, small batch cannabis.
"We are excited to kick off our
pre-roll manufacturing services with the commencement of our agreement with
Experion and expedite the entry of Valens-manufactured dried cannabis products
into the Canadian market," said Tyler Robson, Chief Executive Officer,
Co-Founder and Chair of The Valens Company. "Citizen Stash is synonymous
with best-in-class products and we are proud to be chosen as a partner who can
deliver on customized and premium quality products for the brand."
"We are pleased to work with
Valens as this partnership will allow Experion to expand production to
facilitate broader consumer access to our award-winning Citizen Stash
products," stated Jarrett Malnarich, Chief Executive Officer of Experion
Biotechnologies. "Partnering with an industry leader such as Valens allows
us to immediately multiply our capacity and positions us to quickly develop next
generation product lines. We believe this relationship demonstrates to the
market that we are laser-focused on driving revenue by expanding our capacity
to deliver premium cannabis products across Canada."
The terms of the agreement support a
minimum two-year partnership with monthly minimum order quantities. Valens and
Experion are in continued discussions to expand the existing agreement to
include additional product development and custom manufacturing services for a
range of next generation products beyond gummies, which are currently being
manufactured at the LYF facility, and pre-rolls. There is, however, no
assurance that any such deal would be reached.
PharmaCielo
Ltd. (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer
of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., today provided an update on its operations in
Mexico, in light of the country's continued advancement of legislation to
legalize the use of recreational cannabis in the country. On March 10th,
Mexico's Chamber of Deputies voted 316 to 129 to advance a bill that would
legalize recreational cannabis use in the country (the "Bill"). This
follows the move by Mexico's health ministry in January, to publish a
much-anticipated legal framework for the medical cannabis space, including a
provision for the import of medicinal extracts and products. Through
PharmaCielo S.A. de C.V. ("PharmaCielo Mexico"), a joint venture with
MINO Labs S.A. de C.V. ("MINO Labs"), a specialty pharmaceutical
company and medical supply distributor based in Mexico, the Company is
well-positioned to become a preferred supplier in the country.
Henning
von Koss, CEO of PharmaCielo Ltd.,
commented, "Mexican cannabis legalization has had several stops and starts
since 2018, but with the recent release of medicinal guidelines and Wednesday
night's vote to continue advancing the Bill, the country looks poised to legalize
and become the largest cannabis market in the world, sooner rather than later.
PharmaCielo Mexico is positioned to become a preferred B2B supplier in the
country, backed by PharmaCielo's broad extract portfolio, scale and
flexibility, and MINO Labs' long track record of success in the market."
Manuel
Cosme Odabachian, CEO of MINO Labs, added, "For more than 20
years, MINO Labs has been a leader in the Mexican specialty pharmaceutical
distribution sector. The interest among our existing customer base for high
quality cannabis extracts and value-added formulations has been growing as
Mexican cannabis legalization has advanced over the past two years. We expect
significant demand when the market opens and are very encouraged by the news
that recreational cannabis legalization will continue to move forward, toward
the April deadline provided by the Supreme Court."
PharmaCielo Mexico was established
in 2019 to bring PharmaCielo's high-quality cannabis extracts and derivative
products to the Mexican market, leveraging MINO Labs' extensive experience and
broad presence in the country's pharmaceutical space. Following a Colombian
site visit by MINO Labs in February 2021, PharmaCielo has submitted a request
to initiate the Mexican GMP audit process, which the Company expects to be
complete by the end of Q2'21, depending on the Mexican Authorities'
availability. With the voting of the Bill, PharmaCielo Mexico will immediately
initiate the process to obtain an import license for cannabis products in
Mexico. PharmaCielo is currently producing extracts in compliance with EU-GMP
guidelines.
Distribution of cannabis products by
PharmaCielo in Mexico will be subject to the approval of the TSX Venture
Exchange (the "TSXV").
Investor ideas reminds all
listeners to read our disclaimers and disclosures on the Investorideas.com
website and that this podcast is not an endorsement to buy products or services
or securities. Investors are reminded all investment involves risk and possible
loss of investment.
Learn more about
our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
To hear more
Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
The
Investorideas.com podcasts are also available on iTunes ( Apple Podcasts)
, Audible , Spotify, Tunein, Stitcher,
Spreaker.com, iHeartRadio , Google Play
Music and most audio platforms available.
Potcasts is now a certified
word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that
Inspires Big Investing Ideas
Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts
and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech,
water, renewable energy and more. Investor Idea’s original branded content
includes the following podcasts and columns : Crypto
Corner , Play by Play sports and stock news column, Investor
Ideas Potcasts Cannabis News and Stocks on the Move podcast and
column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news,
articles and equity research as well as creates original content, including
video, interviews and articles. Original content created by investorideas is
protected by copyright laws other than syndication rights. Our site does not
make recommendations for purchases or sale of stocks, services or products.
Nothing on our sites should be construed as an offer or solicitation to buy or
sell products or securities. All investing involves risk and possible losses.
This site is currently compensated for news publication and distribution,
social media and marketing, content creation and more. Disclosure is posted for
each compensated news release, content published /created if required but
otherwise the news was not compensated for and was published for the sole
interest of our readers and followers. Contact management and IR of each company
directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our
other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations
of each country. Please read Investorideas.com privacy policy:
https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow
us on Facebook https://www.facebook.com/Investorideas
Follow
us on YouTube https://www.youtube.com/c/Investorideas
Download
our Mobile App for
iPhone and Android
Join
our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800
665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
No comments:
Post a Comment